Management and outcomes of glioblastoma: 20-year experience in a single Australian institution

被引:2
作者
Lenffer, Bianca [1 ]
Ruben, Jeremy [1 ,2 ]
Senthi, Sashendra [1 ,2 ]
Millar, Jeremy [1 ,2 ,3 ]
Ong, Wee Loon [1 ,2 ,3 ,4 ]
机构
[1] Alfred Hlth Radiat Oncol, Melbourne, Vic, Australia
[2] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia
[3] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia
[4] Alfred Hlth Radiat Oncol, 55 Commercial Rd, Melbourne, Vic 3004, Australia
关键词
chemotherapy; glioblastoma; radiation therapy; surgery; RANDOMIZED PHASE-III; RADIATION-THERAPY; ELDERLY-PATIENTS; ADJUVANT TEMOZOLOMIDE; VICTORIA; 1998-2000; OLDER PATIENTS; RADIOTHERAPY; SURVIVAL; MULTIFORME; RESECTION;
D O I
10.1111/1754-9485.13607
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: We aimed to evaluate the changing patterns in the management of glioblastoma (GBM) and impact on survival outcomes over a 20-year period.Methods: This is a retrospective study of patients diagnosed with GBM between 2001 and 2020, who had radiation therapy (RT) in an Australian institution. The primary outcomes were changes in treatment modalities (including surgery, RT, and chemotherapy) over time and overall survival (OS). Multivariable Cox regressions were used to evaluate factors associated with OS, including age, sex, ECOG performance status, treatment modalities, treatment facility, and year of treatment.Results: 1079 patients were included in this study. Thirty-five per cent of patients had gross total resection, increasing from 31% in 2001-2005 to 45% in 2016-2020 (P < 0.001). Sixty-four per cent of patients had >= 60 Gy RT, increasing from 57% in 2001-2005 to 66% in 2016-2020 (P < 0.001). Seventy-five per cent of patients had chemotherapy, increasing from 22% in 2001-2005 to 89% in 2016-2020 (P < 0.001). Treatment received varied based on patients' age and ECOG performance status. The median OS for the entire cohort was 13.0 months (95% CI = 12.0-13.7). Median OS in patients who had maximal treatment (i.e., gross total resection, >= 60 Gy RT and chemotherapy) was 20.6 months (95% CI = 17.3-22.8). In multivariable analyses, age, sex, treatment facility, extent of surgical resection, RT dose, and chemotherapy use were associated with OS.Conclusion: This is one of the largest Australian series on the management and outcomes of GBM spanning a 20-year period. We observed improvement in OS over time, which is likely associated with evolving treatment options over the study period.
引用
收藏
页码:208 / 216
页数:9
相关论文
共 37 条
[1]   Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis [J].
Almenawer, Saleh A. ;
Badhiwala, Jetan H. ;
Alhazzani, Waleed ;
Greenspoon, Jeffrey ;
Farrokhyar, Forough ;
Yarascavitch, Blake ;
Algird, Almunder ;
Kachur, Edward ;
Cenic, Aleksa ;
Sharieff, Waseem ;
Klurfan, Paula ;
Gunnarsson, Thorsteinn ;
Ajani, Olufemi ;
Reddy, Kesava ;
Singh, Sheila K. ;
Murty, Naresh K. .
NEURO-ONCOLOGY, 2015, 17 (06) :868-881
[2]  
Australian Institute of Health and Welfare (AIHW), 2021, Chronic disease: Overview
[3]   Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial [J].
Bakitas, Marie A. ;
Tosteson, Tor D. ;
Li, Zhigang ;
Lyons, Kathleen D. ;
Hull, Jay G. ;
Li, Zhongze ;
Dionne-Odom, J. Nicholas ;
Frost, Jennifer ;
Dragnev, Konstantin H. ;
Hegel, Mark T. ;
Azuero, Andres ;
Ahles, Tim A. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) :1438-1445
[4]   World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas A Review [J].
Berger, Tamar R. ;
Wen, Patrick Y. ;
Lang-Orsini, Melanie ;
Chukwueke, Ugonma N. .
JAMA ONCOLOGY, 2022, 8 (10) :1493-1501
[5]   Association of the Extent of Resection With Survival in Glioblastoma A Systematic Review and Meta-analysis [J].
Brown, Timothy J. ;
Brennan, Matthew C. ;
Li, Michael ;
Church, Ephraim W. ;
Brandmeir, Nicholas J. ;
Rakszawski, Kevin L. ;
Patel, Akshal S. ;
Rizk, Elias B. ;
Suki, Dima ;
Sawaya, Raymond ;
Glantz, Michael .
JAMA ONCOLOGY, 2016, 2 (11) :1460-1469
[6]  
Cancer Council Victoria and Department of Health Victoria, 2021, Optimal care pathway for men with prostate cancer
[7]   Neuro-oncology practices in Australia: A Cooperative Group for Neuro-Oncology patterns of care study [J].
Chen, James Y. ;
Hovey, Elizabeth ;
Rosenthal, Mark ;
Livingstone, Ann ;
Simes, John .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (02) :162-167
[8]   Food and Drug Administration drug approval summary: Temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme [J].
Cohen, MH ;
Johnson, JR ;
Pazdur, R .
CLINICAL CANCER RESEARCH, 2005, 11 (19) :6767-6771
[9]   Radiotherapy management of patients diagnosed with glioma in Victoria (1998-2000): A retrospective cohort study [J].
Dally, M. ;
Rosenthal, M. ;
Drummond, K. ;
Murphy, M. ;
Cher, L. ;
Ashley, D. ;
Thursfield, V. ;
Giles, G. .
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2009, 53 (03) :318-324
[10]   The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials [J].
Fazzari, Francesco G. T. ;
Rose, Foster ;
Pauls, Mehrnoosh ;
Guay, Evelyne ;
Ibrahim, Mohammed F. K. ;
Basulaiman, Bassam ;
Tu, Megan ;
Hutton, Brian ;
Nicholas, Garth ;
Ng, Terry L. .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 169